Assessment of drug-induced hepatotoxicity in clinical practice: A challenge for gastroenterologists

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 13, Issue 3

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

All Articles published online

Item

Count

PDF

409

HTML

2373

Figures (1-1)

185

Tables (1-6)

155

Sum=3122

Jan 21, 2007 (publication date) through Nov 4, 2024

Times Cited of This Article

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Editorial

World J Gastroenterol. Jan 21, 2007; 13(3): 329-340
Published online Jan 21, 2007. doi: 10.3748/wjg.v13.i3.329

Table 3 Autoantibodies specific to drug-induced hepatotoxicity

Autoantibody	Example
Anti-mitochondrial (anti-M6) autoantibody	Iproniazid
Anti-liver kidney microsomal 2 antibody (anti-LKM2)	Tienilic acid
Anti CYP 1A2	Dihydralazine
Anti CYP 2E1	Halothane
Anti-liver microsomal autoantibody	Carbamazepine
Anti-microsomal epoxide hydrolase	Germander

CYP: Cytochrome P450.

Citation: Andrade RJ, Robles M, Fernández-Castañer A, López-Ortega S, López-Vega MC, Lucena MI. Assessment of drug-induced hepatotoxicity in clinical practice: A challenge for gastroenterologists. World J Gastroenterol 2007; 13(3): 329-340
URL: https://www.wjgnet.com/1007-9327/full/v13/i3/329.htm
DOI: https://dx.doi.org/10.3748/wjg.v13.i3.329